Melatonin and melatonin receptor agonists in the treatment of nocturia: A systematic review

Abstract

AbstractAimCauses of nocturia may extend beyond primary bladder pathology and it has been commonly associated as a side effect of sleep disorders. This has led to the study of melatonin and melatonin receptor agonists as a primary treatment for nocturia hypothesized to be secondary to sleep disorders. We aim to systematically review the efficacy and reported safety of melatonin and melatonin receptor agonists in the treatment of nocturia.MethodsA search strategy of EMBASE and Pubmed/Medline databases was utilized to identify eligible studies. Two thousand and twenty‐eight unique references were identified in concordance with the Preferred Reporting Items of Systematic Reviews and Meta‐Analyses guidelines for systematic reviews, of which nine papers met the inclusion criteria. The Cochrane Collaboration risk of bias criteria in the open label and nonplacebo studies was used to assess bias.ResultsThe nine studies identified included 3 randomized double‐blinded placebo‐controlled trials, 2 randomized non‐placebo trial, and 4 prospective open‐label trials. Three utilized the melatonin‐receptor agonist ramelteon (8 mg) and six utilized melatonin (four 2 mg extended release, two 2 mg normal release). Nocturia improved in 8 studies varying from moderate to low efficacy related to reduction in nocturia episodes. Five studies evaluated sleep parameters finding improvement in both nocturia and sleep quality. Male subjects represented 76.8% of 371 total subjects in prospective and randomized trials. Ramelteon and melatonin were both reported as well tolerated during nocturia treatment. A meta‐analysis was not able to be performed due to the heterogeneity of bladder diagnoses.ConclusionsAt this time, there is insufficient evidence to routinely recommend melatonin as an effective treatment for nocturia given the limitations of current clinical studies. Randomized placebo‐controlled trials and prospective open label studies in non‐neurogenic populations report a trend towards nocturia improvement with good tolerability and rare side effects. Therefore, further larger scale randomized trials with focused urologic diagnoses in well‐characterized patient populations are warranted.